In contrast, patients with a dilated left atrium (LAVi ≥ 40 mL/m 2 ) showed a trend toward worse outcomes with propafenone, including higher 1-month mortality (HR 3.6, p = 0.045) and slower cardioversion (median 18 h vs. 6.4 h with amiodarone, p = 0.05) ( 56 ).
Overall 28-day mortality showed borderline significance (RR 0.83, 95% CI 0.68–1.00, p = 0.05), with single-center trials favoring beta-blockade but multicenter trials showing neutral or harmful effects.
The primary endpoint, the proportion of patients achieving sinus rhythm at 24 h, was met by 72.8% in the propafenone group and 67.3% in the amiodarone group, a difference that did not reach statistical significance ( p = 0.4).